VEGFC Mouse Monoclonal Antibody [Clone ID: OTI4A1]

SKU CF801089

Carrier-free (BSA/glycerol-free) VEGFC mouse monoclonal antibody, clone OTI4A1 (formerly 4A1)

Product Data

• Clone Name: OTI4A1
• Application: IHC, WB
• Recommended Dilution: WB 1:200
• Reactivity: Human, Mouse, Rat
• Antibody Host: Mouse
• Isotype: IgG1
• Clonality: Monoclonal
• Immunogen: Human recombinant protein fragment corresponding to amino acids 112-227 of human VEGFC (NP_005420) produced in E.coli.
• Buffer: Lyophilized powder (original buffer 1X PBS, pH 7.3, 8% trehalose)
• Reconstitution Method: For reconstitution, we recommend adding 100uL distilled water to a final antibody concentration of about 1 mg/mL. To use this carrier-free antibody for conjugation experiment, we strongly recommend performing another round of desalting process. (OriGene recommends Zeba Spin Desalting Columns, 7KMWCO from Thermo Scientific)
• Purification: Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G)
• Conjugation: Unconjugated
• Storage: Store at -20°C as received.
• Stability: Stable for 12 months from date of receipt.
• Shipping: Ambient
• Predicted Protein Size: 46.7 kDa
• Gene Name: vascular endothelial growth factor C
• Database Link:
  NP_005420
  P49767
• Background: The protein encoded by this gene is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family, is active in angiogenesis and endothelial cell growth, and can also affect the permeability of blood vessels. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms which bind and activate VEGFR-3 receptors. Only the fully processed form can bind and activate VEGFR-2 receptors. This protein is structurally and functionally similar to vascular endothelial growth factor D. [provided by RefSeq, Jul 2008]
• Synonyms: Flt4-L; LMPH1D; VRP

Reference Data

• Protein Families: Druggable Genome, Secreted Protein
• Protein Pathways: Bladder cancer, Cytokine-cytokine receptor interaction, Focal adhesion, mTOR signaling pathway, Pancreatic cancer, Pathways in cancer, Renal cell carcinoma